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Aim: To identify the most common therapeutic options for the treatment of early-stage
mycosis fungoides in Spain, quantify their associated healthcare resource use and costs.
Methods: After reviewing the literature, a panel of 6 Spanish clinical dermatologists validated the
treatments and healthcare resource use through a structured questionnaire. Individual responses
were collected, analyzed and presented into a face-to-face meeting in order to reach a consensus.
Cost categories considered were: drug acquisition and administration, photo/radiotherapy session
and maintenance, clinical follow-up visits and laboratory tests. Costs were expressed in euros from
2018. The Spanish National Health System perspective was considered, taking into account direct
health costs and time horizons of 1, 3 and 6 months.
Results: Costs for the skin-directed treatments (SDT) assessed at 1, 3 and 6 months, were:
Topical carmustine [€6,593.36, €19,780.09 and €27,592.78]; Phototherapy with psoralens and
ultraviolet A light (PUVA) [€1,098.68, €2,999.99 and €3,187.60]; Narrow-band ultraviolet
B phototherapy [€1,657.47, €4,842.10 and €4,842.10]; Total skin electron beam therapy
(TSEBT) [€6,796.45, €7,913.34 and €7,913.34]. Cost for topical corticosteroids, being consid-
ered an adjuvant option, were €17.16, €51.49 and €102.97. Costs for the assessed systemic
treatments alone or in combination with SDT at 1, 3 and 6 months, were: Systemic retinoids
[€2,026.03, €5,206.63 and €7,426.42]; Systemic retinoids + PUVA phototherapy [€3,066.50,
€8,271.26 and €10,046.58]; Interferon alfa + PUVA phototherapy [€1,541.09, €5,167.57 and
€6,404.55].
Conclusion: According to the Spanish clinical practice, phototherapies in monotherapy
were the treatments with the lowest associated costs regardless of the time horizon consid-
ered. TSEBT turned out as the treatment with the highest associated costs when considering
1 month. However, while considering 3 and 6 months the treatment with the highest
associated costs was topical carmustine. The results of this analysis may provide critical
information to measure the disease burden, to detect unmet medical needs and to advocate
towards better treatments for this rare disease.
Keywords: health care costs, health resources, mycosis fungoides, lymphoma, T-cell,
cutaneous, surveys and questionnaires, Spain
Introduction
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of diseases that repre-
sent between 1–4% of cases of non-Hodgkin lymphomas.1–5 CTCLs are characterized by
the primary infiltration ofmalignant Tcells in the skinwithout evidence of extracutaneous
disease at the time of diagnosis.1,6,7
Mycosis fungoides (MF) represents between 50–70% of cases of CTCL,3,8–11
being classified as a rare disease.12,13 Although prevalence is difficult to
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determine, the age-adjusted incidence of MF is estimated
to be between 0.12 and 0.55 cases per 100,000
inhabitants.14–17 The low incidence rate of CTCLs
means it is essential to create multicenter records in
order to shed light on the characteristics of patients
affected by this group of diseases, to describe their state
of health and clinical burden and to have a better under-
standing of their management and prognosis.18,19 This
has led to the Spanish Academy of Dermatology and
Venerology (AEDV) setting up a registry of patients
with primary skin lymphomas. It recently published the
results from its first year in operation: by
December 2017, the registry contained information on
639 patients with primary skin lymphomas from 16
University Hospitals. Among the 348 recorded MF
patients, the most common diagnosis was classical MF
(77.3%), most of them (83.6%) presented early stages of
the disease (IA-IIA).20
In most cases, MF initially presents as an indolent
condition with slow progression that tends to start with
a patch phase, progressing in some patients to infiltrated
plaques and finally evolving into a tumoral phase.1,21–23
The prognosis depends on the disease stage as determined
by the International Society for Cutaneous Lymphomas
(ISCL) and the European Organization for Research and
Treatment of Cancer (EORTC).6,24
As the disease progresses, a detrimental effect on sur-
vival has been observed among MF patients.25–29
Although patients with limited T1 stage MF present
a similar life expectancy to the control populations,25,27
generally patients with MF present accumulated survival
rates significantly lower compared to the healthy popula-
tion matched by age and sex.25
Treatment strategies for MF can be split into two
categories: skin-directed treatments (SDT) and systemic
treatments including biological response modifiers, single
or multiple chemotherapies, epigenetic therapies, mono-
clonal antibodies and hematopoietic stem cell
transplantation.11,30,31 Despite the availability of multiple
treatment options, none of these may be considered as
standard.32 Patients with limited-stage disease are usually
treated with SDT, while patients with advanced stage MF
require a broader multidisciplinary approach involving
various combinations of SDT, biological response modi-
fiers and systemic chemotherapy.11,30–32
MF presents a significant clinical burden for patients with
this rare disease. Patients not only feel overwhelmed by the
physical symptoms of the disease but also suffer from sleep
problems because of itching,8,33 and experience a significant
emotional impact caused by frustration and rejection of their
disease.33,34 MF has an impact on patients’ functional cap-
ability and the ability to carry out daily activities. It also has
a negative effect on patients’ productivity, causing work
absenteeism or interfering with their productivity.8
In financial terms,MF involves a significant burden both to
patients as well as to healthcare systems. Although patients
with advanced stage MF incur higher healthcare costs than
patients at the early stages, it has been shown that MF patients
with less severe stages may also require high use of healthcare
resources because of numerous visits to outpatient care centers
and pharmacy departments.35–37 In addition, treating MF may
be a social economic strain because of transport direct costs
and indirect costs associated with loss of productivity,38 all
depending on their geographic location, the type of treatment
and the characteristics of the healthcare system.
This, together with the lack of financial studies in
Spain on this rare disease, has motivated this study with
the aim of identifying the therapeutic alternatives most
commonly used in Spain for managing patients with early-
stage MF, to determine their associated healthcare
resources use and to quantify their associated costs.
Materials and methods
Study design
Firstly, a structured review of medical literature was car-
ried out to determine the available clinical and financial
evidence on CTCLs and MF, and to draw up a structured
questionnaire with the aim of defining the most commonly
used treatment alternatives in Spain for managing patients
with early stages of MF, to determine their healthcare
resources use and to quantify their associated costs.
A panel of 6 clinical dermatology experts from the
Spanish setting with a wealth of experience in managing
CTCL and MF was put together. After completing and
returning the questionnaires, the individual responses
were assessed and grouped to obtain data considered in
the analysis. A face-to-face meeting was set up to present
and validate the responses obtained and to reach consensus
on the grouped responses. The identity of the members of
the expert panel was kept secret by the team responsible
for the research until the face-to-face meeting (Figure 1).
Therapeutic options
From the evidence available, the main treatments used in
Spanish clinical practice for early-stage MF are:
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phototherapy with psoralen and ultraviolet A light
(PUVA), phototherapy with narrowband ultraviolet
B light (NB-UVB), total skin electron beam therapy
(TSEBT), topical corticosteroids, systemic retinoids,
a combination of PUVA phototherapy with systemic reti-
noids or interferon alfa (IFNα), as well as, to a lesser
extent, topical carmustine-based chemotherapy.
Questionnaire
The questionnaire consisted of a total of 72 questions requested
as qualitative questions to confirmdata frommedical literature,
quantitative questions, and open-ended questions. The numer-
ical responses were grouped and the average data, standard
deviation, median, minimum and maximum data were esti-
mated. The qualitative responses were grouped according to
the following criteria: unanimous response (the whole expert
panel [100%] in agreement), consensus (at least 83% of the
expert panel gave the same response but without being unan-
imous), majority (response indicated by a majority of the
expert panel, that is between 66% and 83%) and discrepancy
(all other possible situations: namely, where the same response
was not shared by at least 66% of the experts panel). All
members of the expert panel provided their informed consent
to participate in this study and to complete the questionnaire.
Type of analysis
Treatment cost analysis was carried out from the perspec-
tive of the Spanish National Health System. Therefore, the
direct healthcare costs were taken into account. The
Spanish expert panel considered that adopting one-year
time horizon would not be appropriate for this analysis.
During one-year timeframe, different MF-CTCL treat-
ments may be used in combination or alternately.
Therefore, according to the most commonly established
follow-up timeframes and treatment durations, using time
horizons of 1, 3 and 6 months would be the best approach
to capture and reflect healthcare resource usage within
MF-CTCL patients being managed in the Spanish setting.
Costs
Cost categories used for analysis were: pharmaceutical costs,
administration-related costs, costs for each session of photo-
therapy or radiotherapy, costs attributable to their maintenance,
and costs associated with follow-up visits and laboratory tests.
This analysis has only taken into account costs derived from the
healthcare resources differentially required by each treatment,
excluding any costs attributable to all treatments assessed. For
medicinal products dispensed by community pharmacies, retail
prices were used, whereas for medicinal products used in the
hospital setting, the reported ex-factory priceswere used includ-
ing the Royal Decree-Law 8/2010 deduction.39 Vial optimiza-
tion (ie, residual or non-vial wastage)was taken into account for
medicinal products requiring parenteral administration. Unit
costs were obtained from tariffs published by the autonomous
communities, from the SpanishGeneral Council for the Official
College of Pharmacists database and medical literature pub-
lished in the Spanish setting.40–47 All costs are given in euros
for the year 2018 (Table 1).
Patient characteristics
Clinical experts unanimously confirmed that the mean body
surface area and mean weight of an adult patient with early-
stage MF should be equivalent to the Spanish adult population,
namely 1.81 m2 and 72.88 kg.48 In order to be able to estimate
the corticosteroids consumption, a baseline body surface area
involvement of 11% (range 2%-17%) was considered to be
representative for an early-stage MF patient.49,50 All inputs
considered in the current study were available from the litera-
ture and validated through an expert panel. Therefore, this study
did not require ethical review board or committee approval




The human and equipment resources involved in the acquisi-
tion, management, compounding, monitoring and dispensing
• Including 6 clinical dermatology experts from the Spanish setting
• Treatment alternatives definition for early MF-CTCL management in Spain
• Healthcare resources use determination for each treatment
• Individual responses were assessed and grouped
• Queries were generated when detecting unclear responses
• Responses obtained were presented in order to reach consensus




4. Aggregation and responses analysis
5. Face-to-face meeting
• Early MF-CTCL treatment costs results were presented and validated by the 
expert panel
6. Final report
Figure 1 Study diagram.
Abbreviations: CTCL, cutaneous T-cell lymphomas; MF, mycosis fungoides.
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processes of various topical carmustine-compounded prepara-
tions were taken into account. Their usage distribution, their
mean daily dose and time until achieving complete response
(CR) were also included. Laboratory tests and follow-up visits
were also considered (Table S1).44,51–55
Phototherapies (PUVA and NB-UVB)
The weekly frequency and number of phototherapy ses-
sions, together with the mean duration until achieving CR
were considered for PUVA and NB-UVB. Laboratory tests
and follow-up visits were taken into account. For PUVA-
based phototherapy, it was agreed that for the base case, no
patient would receive maintenance treatment with PUVA
after achieving CR (Table S2).56–61
Total skin electron beam therapy
The usage distribution, treatment duration and number of
sessions until achieving CR of various TSEBT schedules
were taken into consideration. Laboratory tests and follow-
up visits were also taken into account (Table S3).62–67
Table 1 Unit costs








Acitretin OR (mg) 0.05 0.04 0.06 40
Alitretinoin OR (mg) 0.96 0.48 1.43
Beclomethasone TP (g) 0.05 0.04 0.08
Betamethasone TP (g) 0.07 0.05 0.09
Bexarotene OR (mg) 0.14 0.11 0.16
Carmustine IV (100 mg vial) 1,405.00 1,124.00 1,686.00
Clobetasol TP (g) 0.08 0.07 0.10
Diflorasone TP (g) 0.08 0.06 0.09
Statins OR (tablet)a 0.11 0.11 0.12
Fenofibrate OR (tablet) 0.18 0.18 0.22
Fluocinolone TP (g) 0.12 0.04 0.24
Fluticasone TP (g) 0.15 0.12 0.18
IFNα (MIU) 3.96 3.82 4.11
Isotretinoin OR (mg) 0.04 0.04 0.04
Levothyroxine OR (tablet) 0.04 0.02 0.07
Methylprednisolone TP (g) 0.16 0.14 0.19
Mometasone TP (g) 0.08 0.08 0.08
Triamcinolone TP (g) 0.30 0.19 0.39
Imaging and laboratory
tests
Complete biochemistry 91.41 29.32 182.88 41
ANA level 27.39 15.00 38.01
Calcium/vitamin D level 31.07 12.26 42.88
Cortisol level 9.58 6.16 14.00
Creatinine level 2.84 0.48 7.30
Liver function testb 22.92 5.01 63.88
Thyroid function testc 24.95 15.23 43.32




Lymphoid phenotype 58.69 24.00 107.06
Phototest/photopatch 85.81 78.00 94.25
Chest X-ray 25.97 9.15 84.00
CT scan of abdomen and
pelvis
254.19 62.00 484.88
Pregnancy test 8.38 5.00 11.30
Visit and clinical
assessments




Ophthalmology review 51.55 47.00 56.09
Following psychiatric review 47.91 26.00 82.00
Treatment consultations
PUVA session 87.37 44.00 151.96 41
NB-UVB session 136.08 44.00 195.25




30.51 19.09 41.93 42
(Continued)
Table 1 (Continued).

















16.60 14.61 19.92 44
Ethanol 96 (mL) 0.03 0.02 0.03 40
Sterilized/White petroleum
jelly (g)
0.10 0.04 0.29 40
Vacuflasc® 500 mL sterile
flask (unit)
5.51 4.41 6.61 45
Needles (unit) 0.12 0.04 0.22 46
Absorbent sterile cotton
gauze (unit)
0.06 0.05 0.06 40
Gloves (unit) 0.04 0.00 0.07 47
Notes: aConsidering equivalent usage distribution between atorvastatin 10 mg/day and
simvastatin 20 mg/day. bIncludes the following assessment: aspartate aminotransferase,
alanine amino transferase, gamma glutamyl transferase, alkaline phosphatase, bilirubin,
albumin and prothrombin time. cIncludes the following assessments: thyroxine and thyro-
tropin dConsidering the partial attribution method.
Abbreviations: ANA, antinuclear antibodies; IFNα, interferon alfa; IV, intravenous;
MIU, million international units; OR, oral; PUVA, psoralens with ultraviolet A light;
TSEB, total skin electron beam; CT, computerized axial tomography scan; TG,
triglycerides; TP, topical; NB-UVB, narrowband ultraviolet B light.
Ortiz-Romero et al Dovepress
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Topical corticosteroids
The distribution of topical corticosteroids authorized and
commercialized in Spain, the amount of product required
for topical application and the laboratory tests and follow-
up visits were taken into account.40,68–70 It was estimated
that the amount of cream or gel that fits on the tip of
a finger (0.5 g) would be enough to treat the surface of
both of the patient’s hands, equivalent to 2% of body
surface area (Table S4).71
Systemic treatments alone or in
combination with SDT
Systemic retinoids
The usage distribution and dose of systemic retinoids author-
ized and commercialized in Spain were considered.
Additionally, the median duration of treatments, the use of
concomitant treatments, together with the laboratory tests and
follow-up visits were taken into account (Table S5).70,72–75
Systemic retinoids in combination with PUVA
phototherapy
The weekly frequency, number of sessions and mean duration
until achieving CR of PUVA phototherapy (in combination
with systemic retinoids) were considered. In addition, the
usage distribution and dose of systemic retinoids authorized
and commercialized in Spain, while been used in combination
with PUVA phototherapy to treat MF-CTCL, were taken into
account. Concomitant treatments, laboratory tests and follow-
up visits were also considered (Table S6).76
IFNα in combination with PUVA phototherapy
The mean duration until achieving CR, together with the
IFNα dose from authorized and commercialized presenta-
tions in Spain were taken into account. The clinical evidence
identified from medical literature would not allow us to
determine the number of PUVA sessions (in combination
with IFNα) needed to achieve the CR.77–79 Thus, it was
conservatively assumed that the weekly frequency of
PUVA sessions in combination with IFNα would be equiva-
lent to PUVA in monotherapy. PUVA exposure was not
considered until patients had reached the end of the third
week of IFNα treatment. Laboratory tests and follow-up
visits were also taken into consideration (Table S7).77
Sensitivity analysis
In order to highlight the difficulties to achieve consensus
regarding whether or not to include a maintenance regimen
in PUVA-based phototherapy treatment, a sensitivity
analysis scenario taking into account that a reduced per-
centage (10%) of MF patients in the Spanish setting would
continue to receive PUVA maintenance therapy after
achieving CR has been carried out.
Likewise, it was suggested that a multivariate extreme
sensitivity analysis should be carried out in order to estimate
treatment costs from scenarios that took into account the
extreme parameters (unit cost and use of resources): the
most optimistic case possible (minimum scenario) compared
with the most pessimistic case possible (maximum scenario).
For the healthcare use of resources, the range of variation
obtained by the expert panel was taken into account. For
costs, the extreme values (minimum and maximum) of the
source used, or where this was not available, a variation of
±20% of the base case cost, were considered.
Results
The base case results obtained for time horizons at 1, 3 and
6 months, respectively, are presented below. For each time
horizon, the results obtained for minimum and maximum
scenarios based on the multivariate extreme sensitivity
analysis are shown in brackets.
Skin-directed treatments
Topical carmustine
The treatment cost for carmustine-based topical chemotherapy
was €6,593.36 (€2,411.12-€10,814.51), €19,780.09
(€2,411.12-€32,443.54) and €27,592.78 (€2,411.12-
€64,887.08) for time horizons of 1, 3 and 6 months, respec-
tively. Pharmaceutical costs were the main component of
treatment cost (≥99.79% of the total cost, in all cases)
(Table 2).
Phototherapies (PUVA and NB-UVB)
As a base case, the treatment cost for PUVA treatment was
€1,098.68 (€538.10-€2,328.99), €2,999.99 (€1,453.29-
€6,294.46) and €3,187.60 (€1,453.29-€8,559.67) for time
horizons of 1, 3 and 6 months, respectively. The cost of
phototherapy sessions represented the main component of
treatment cost (between 85.05% and 95.87% of the total
cost, depending on the case) (Table 2).
As an alternative scenario, if 10% of MF patients con-
tinued receiving PUVA maintenance treatment after reach-
ing CR, PUVA treatment cost would be €1,098.68,
€2,999.99 and €3,294.00 for time horizons 1, 3 and 6
months, respectively. Time horizons at 1 and 3 months
(4.35 and 13.04 weeks, respectively) were not enough to
exceed the mean duration until achieving CR (13.89 weeks).
Dovepress Ortiz-Romero et al
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Therefore, alternative scenario results showed a slight dif-
ference to the base case (3.34% increase) only for the
6-month time horizon.
As shown in Table 2, the treatment cost for NB-UVB
treatment was €1,657.47 (€651.13-€2,217.01), €4,842.10
(€1,296.46-€6,594.27) and €4,842.10 (€1,296.46-€8,782.89)
for time horizons of 1, 3 and 6 months, respectively.
Phototherapy sessions costs were the main component of
treatment cost (≥97.05% of the total cost, in all cases).
Total skin electron beam therapy
The cost of TSEBT was €6,796.45 (€4,415.84-€9,454.26)
considering 1-month time horizon, and €7,913.34
(€5,237.05-€10,923.46) when considering 3 and 6 months
time horizons. TSEBT sessions costs represented the main
component of the treatment cost (between 86.43% and
97.84% of the total cost, depending on the case) (Table 2).
Topical corticosteroids
Cost of topical corticosteroids was €17.16 (€4.83-€78.09),
€51.49 (€14.50-€234.26) and €102.97 (€28.99-€468.53)
for time horizons of 1, 3 and 6 months, respectively.
Pharmaceutical costs represented the main cost component
(between 92.94% and 98.24% of the total cost, depending
on the case) (Table 2).
Systemic treatments alone or in
combination with SDT
Systemic retinoids
The cost of treatment with systemic retinoids was €2,026.03
(€479.40-€4,172.65), €5,206.63 (€479.40-€10,120.12) and
€7,426.42 (€479.40-€19,041.32) for time horizons of 1, 3
and 6 months, respectively. Pharmaceutical costs were the
main component of the treatment cost (between 63.75% and
88.50% of the total cost, depending on the case) (Table 3).
Systemic retinoids in combination with PUVA
phototherapy
The cost of combined treatment based on PUVA photother-
apy together with systemic retinoids was €3,066.50
(€1,698.48-€5,260.62), €8,271.26 (€4,860.29-€13,316.38)
and €10,046.58 (€5,938.77-€16,064.16) for time horizons
of 1, 3 and 6 months, respectively. Pharmaceutical costs
attributed to systemic retinoids together with phototherapy
sessions costs represented the main component of the treat-
ment cost (between 70.57% and 96.83% of the total cost,
depending on the case) (Table 3).
IFNα in combination with PUVA phototherapy
The cost of combined treatment based on PUVA phototherapy
together with IFNα was €1,541.09 (€1,009.75-€2,756.10),
€5,167.57 (€3,361.65-€9,742.06) and €6,404.55 (€4,163.87-
€12,124.95) for time horizons of 1, 3 and 6 months, respec-
tively. Pharmaceutical and administration costs attributed to
IFNα together with phototherapy sessions costs were the main
component of the treatment cost (between 84.20% and
97.78% of the total cost, depending on the case) (Table 3).
Discussion
As shown in Figure 2, topical corticosteroids followed by
PUVA and NB-UVB phototherapies were, regardless of
the established time horizon, the treatments with the low-
est associated direct healthcare costs. In contrast, when
considering 1-month time horizon, the treatment with the
highest direct healthcare cost was TSEBT, a rescue treat-
ment used in early-stage MF patients in the Spanish set-
ting. When considering time horizons for 3 and 6 months,
the treatment with the highest direct healthcare costs was
carmustine-based topical chemotherapy. In summary, topi-
cal corticosteroids and phototherapies remain among the
treatments with the least direct healthcare costs associated
with the management of early-stage MF patients. In con-
trast, systemic retinoids, PUVA in combination with sys-
temic retinoids or IFNα, TSEBT and particularly, topical
carmustine-based chemotherapy are among the treatments
with the highest direct healthcare costs.
For topical application treatments, when pharmaceuti-
cal costs were divided by their respective time horizon, the
results remained equal. Consequently, pharmaceutical
costs of topical treatments present a time-proportional
cost. For the remaining treatments, costs were allocated
based on the number of phototherapy or radiotherapy ses-
sions, or the time until achieving CR, which justifies that
certain costs remain equivalent over various time horizons.
For example, in the case of phototherapies, costs were
allocated based on the mean duration until achieving CR
(13.89 weeks [12.64 weeks-18.00 weeks] and 12.81 weeks
[8.77 weeks-17.38 weeks] for PUVA and NB-UVB,
respectively). For this reason, for the minimum scenario,
both phototherapies presented the same cost at 3 and 6
months. However, this equivalence was only maintained
for NB-UVB phototherapy in the base case results. The
time horizons adopted in the present analysis were estab-
lished according to the most common follow-up time-
frames, treatment durations and time until complete
Ortiz-Romero et al Dovepress
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Table 2 Estimated costs for skin-directed treatments
Base case Minimum scenario Maximum scenario
€, 2018 % €, 2018 % €, 2018 %
Topical carmustine
Time horizon: 1 month
Pharmaceutical costs 6,582.28 99.83% 2,408.77 99.90% 10,791.71 99.79%
Lab tests and follow-up visits costs 11.09 0.17% 2.34 0.10% 22.80 0.21%
Total cost 6,593.36 100.00% 2,411.12 100.00% 10,814.51 100.00%
Time horizon: 3 months
Pharmaceutical costs 19,746.83 99.83% 2,408.77 99.90% 32,375.13 99.79%
Lab tests and follow-up visits costs 33.27 0.17% 2.34 0.10% 68.41 0.21%
Total cost 19,780.09 100.00% 2,411.12 100.00% 32,443.54 100.00%
Time horizon: 6 months
Pharmaceutical costs 27,546.37 99.83% 2,408.77 99.90% 64,750.27 99.79%
Lab tests and follow-up visits costs 46.41 0.17% 2.34 0.10% 136.81 0.21%
Total cost 27,592.78 100.00% 2,411.12 100.00% 64,887.08 100.00%
PUVA phototherapy
Time horizon: 1 month
Phototherapy sessions costs 949.13 86.39% 477.98 88.83% 1,980.91 85.05%
Lab tests and follow-up visits costs 148.03 13.47% 58.90 10.95% 346.25 14.87%
Associated maintenance costs 1.52 0.14% 1.22 0.23% 1.83 0.08%
Total cost 1,098.68 100.00% 538.10 100.00% 2,328.99 100.00%
Time horizon: 3 months
Phototherapy sessions costs 2,847.39 94.91% 1,390.84 95.70% 5,942.72 94.41%
Lab tests and follow-up visits costs 148.03 4.93% 58.90 4.05% 346.25 5.50%
Associated maintenance costs 4.57 0.15% 3.55 0.24% 5.49 0.09%
Total cost 2,999.99 100.00% 1,453.29 100.00% 6,294.46 100.00%
Time horizon: 6 months
Phototherapy sessions costs 3,034.70 95.20% 1,390.84 95.70% 8,205.84 95.87%
Lab tests and follow-up visits costs 148.03 4.64% 58.90 4.05% 346.25 4.05%
Associated maintenance costs 4.87 0.15% 3.55 0.24% 7.58 0.09%
Total cost 3,187.60 100.00% 1,453.29 100.00% 8,559.67 100.00%
NB-UVB phototherapy
Time horizon: 1 month
Phototherapy sessions costs 1,632.51 98.49% 631.91 97.05% 2,186.80 98.64%
Lab tests and follow-up visits costs 23.43 1.41% 18.00 2.76% 28.38 1.28%
Associated maintenance costs 1.52 0.09% 1.22 0.19% 1.83 0.08%
Total cost 1,657.47 100.00% 651.13 100.00% 2,217.01 100.00%
Time horizon: 3 months
Phototherapy sessions costs 4,814.17 99.42% 1,276.00 98.42% 6,560.40 99.49%
Lab tests and follow-up visits costs 23.43 0.48% 18.00 1.39% 28.38 0.43%
Associated maintenance costs 4.49 0.09% 2.46 0.19% 5.49 0.08%
Total cost 4,842.10 100.00% 1,296.46 100.00% 6,594.27 100.00%
Time horizon: 6 months
Phototherapy sessions costs 4,814.17 99.42% 1,276.00 98.42% 8,747.20 99.59%
Lab tests and follow-up visits costs 23.43 0.48% 18.00 1.39% 28.38 0.32%
Associated maintenance costs 4.49 0.09% 2.46 0.19% 7.32 0.08%
Total cost 4,842.10 100.00% 1,296.46 100.00% 8,782.89 100.00%
(Continued)
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response of the treatments assessed. Adopting one-year
time horizon would not be appropriate for this analysis,
as during one-year timeframe different MF-CTCL treat-
ments could be used in combination or alternately. To
establish one-year therapeutic pattern common for all MF-
CTCL patients in Spain would be practically unfeasible
due to the highly individualized therapeutic approach of
this rare disease in the Spanish clinical setting. Therefore,
considering horizons of 1, 3 and 6 months would be the
best approach to capture and reflect healthcare resource
usage within MF-CTCL patients being managed in the
Spanish setting. The authors encourage the development
of future studies to provide data regarding the time to
progression or initiation of subsequent MF-CTCL treat-
ments, especially among early-stage patients. This could
enhance the development of further economic studies.
The results of this analysis are always shown together
with their respective extreme scenarios. These scenarios,
although unlikely to occur, are intended to estimate bor-
derline situations that may arise when considering the
extreme ranges for all parameters and assumptions taken
into account. The application of extreme sensitivity sce-
narios allows us to assess the uncertainty associated with
these parameters and assumptions. The results from these
sensitivity scenarios must be considered with caution,
particularly avoiding cross-comparisons. Despite this, in
general terms, the results observed in the extreme scenar-
ios are consistent with the conclusions from the base case,
namely that topical corticosteroids and both phototherapies
remain among the lowest direct healthcare cost associated
with early-stage MF treatment. In contrast, TSEBT and
topical carmustine-based chemotherapy remain among the
Table 2 (Continued).
Base case Minimum scenario Maximum scenario
€, 2018 % €, 2018 % €, 2018 %
TSEBT
Time horizon: 1 month
Radiotherapy sessions costs 6,279.56 92.39% 4,303.19 97.45% 8,171.01 86.43%
Lab tests and follow-up visits costs 516.89 7.61% 112.66 2.55% 1,283.25 13.57%
Total cost 6,796.45 100.00% 4,415.84 100.00% 9,454.26 100.00%
Time horizon: 3 months
Radiotherapy sessions costs 7,395.28 93.45% 5,124.05 97.84% 9,638.17 88.23%
Lab tests and follow-up visits costs 518.06 6.55% 113.00 2.16% 1,285.28 11.77%
Total cost 7,913.34 100.00% 5,237.05 100.00% 10,923.46 100.00%
Time horizon: 6 months
Radiotherapy sessions costs 7,395.28 93.45% 5,124.05 97.84% 9,638.17 88.23%
Lab tests and follow-up visits costs 518.06 6.55% 113.00 2.16% 1,285.28 11.77%
Total cost 7,913.34 100.00% 5,237.05 100.00% 10,923.46 100.00%
Topical corticosteroids
Time horizon: 1 month
Pharmaceutical costs 16.33 95.16% 4.49 92.94% 76.71 98.24%
Lab tests and follow-up visits costs 0.83 4.84% 0.34 7.06% 1.37 1.76%
Total cost 17.16 100.00% 4.83 100.00% 78.09 100.00%
Time horizon: 3 months
Pharmaceutical costs 49.00 95.16% 13.47 92.94% 230.14 98.24%
Lab tests and follow-up visits costs 2.49 4.84% 1.02 7.06% 4.12 1.76%
Total cost 51.49 100.00% 14.50 100.00% 234.26 100.00%
Time horizon: 6 months
Pharmaceutical costs 97.99 95.16% 26.95 92.94% 460.29 98.24%
Lab tests and follow-up visits costs 4.98 4.84% 2.05 7.06% 8.24 1.76%
Total cost 102.97 100.00% 28.99 100.00% 468.53 100.00%
Abbreviations: PUVA, psoralens with ultraviolet A light; NB-UVB, narrowband ultraviolet B light; TSEBT, total skin electron beam therapy.
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Table 3 Estimated costs for systemic treatments alone or in combination with skin-directed treatments
Base case Minimum scenario Maximum scenario
€, 2018 % €, 2018 % €, 2018 %
Systemic retinoids
Time horizon: 1 month
Pharmaceutical costs 1,495.16 73.80% 367.28 76.61% 2,660.22 63.75%
Lab tests and follow-up visits costs 530.87 26.20% 112.13 23.39% 1,512.43 36.25%
Total cost 2,026.03 100.00% 479.40 100.00% 4,172.65 100.00%
Time horizon: 3 months
Pharmaceutical costs 4,485.47 86.15% 367.28 76.61% 7,980.66 78.86%
Lab tests and follow-up visits costs 721.16 13.85% 112.13 23.39% 2,139.45 21.14%
Total cost 5,206.63 100.00% 479.40 100.00% 10,120.12 100.00%
Time horizon: 6 months
Pharmaceutical costs 6,572.46 88.50% 367.28 76.61% 15,961.33 83.82%
Lab tests and follow-up visits costs 853.96 11.50% 112.13 23.39% 3,079.99 16.18%
Total cost 7,426.42 100.00% 479.40 100.00% 19,041.32 100.00%
Systemic retinoids in combination with PUVA phototherapy
Time horizon: 1 month
Pharmaceutical costs (retinoids, OR) 1,983.69 64.69% 1,442.15 84.91% 2,474.47 47.04%
Phototherapy sessions costs 522.02 17.02% 119.49 7.04% 1,238.07 23.53%
Lab tests and follow-up visits costs 559.27 18.24% 135.62 7.98% 1,546.25 29.39%
Associated maintenance costs 1.52 0.05% 1.22 0.07% 1.83 0.03%
Total cost 3,066.50 100.00% 1,698.48 100.00% 5,260.62 100.00%
Time horizon: 3 months
Pharmaceutical costs (retinoids, OR) 5,951.06 71.95% 4,326.45 89.02% 7,423.41 55.75%
Phototherapy sessions costs 1,566.07 18.93% 358.48 7.38% 3,714.20 27.89%
Lab tests and follow-up visits costs 749.56 9.06% 171.70 3.53% 2,173.28 16.32%
Associated maintenance costs 4.57 0.06% 3.66 0.08% 5.49 0.04%
Total cost 8,271.26 100.00% 4,860.29 100.00% 13,316.38 100.00%
Time horizon: 6 months
Pharmaceutical costs (retinoids, OR) 7,304.31 72.70% 5,310.27 89.42% 9,111.47 56.72%
Phototherapy sessions costs 1,922.18 19.13% 440.00 7.41% 4,558.80 28.38%
Lab tests and follow-up visits costs 814.47 8.11% 184.01 3.10% 2,387.15 14.86%
Associated maintenance costs 5.61 0.06% 4.49 0.08% 6.73 0.04%
Total cost 10,046.58 100.00% 5,938.77 100.00% 16,064.16 100.00%
IFNα in combination with PUVA phototherapy
Time horizon: 1 month
Pharmaceutical costs (IFNα) 429.21 27.85% 413.55 40.96% 704.92 25.58%
Administration costs (IFNα) 397.72 25.81% 248.85 24.65% 546.59 19.83%
Phototherapy sessions costs 512.27 33.24% 257.98 25.55% 1,069.15 38.79%
Lab tests and follow-up visits costs 200.37 13.00% 88.15 8.73% 433.61 15.73%
Associated maintenance costs 1.52 0.10% 1.22 0.12% 1.83 0.07%
Total cost 1,541.09 100.00% 1,009.75 100.00% 2,756.10 100.00%
Time horizon: 3 months
Pharmaceutical costs (IFNα) 1,358.94 26.30% 1,309.36 38.95% 2,632.24 27.02%
Administration costs (IFNα) 1,193.16 23.09% 746.56 22.21% 1,639.76 16.83%
Phototherapy sessions costs 2,410.53 46.65% 1,213.93 36.11% 5,030.96 51.64%
Lab tests and follow-up visits costs 200.37 3.88% 88.15 2.62% 433.61 4.45%
(Continued)
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treatments with the highest direct healthcare costs. The
sensitivity scenarios pointed out a high sensitivity of the
results obtained in the present study to those parameters
related to application patterns, treatment duration and time
to achieve complete response.
The results of this analysis have shown that the most
commonly used treatments in Spanish clinical practice
during the early stages of MF represent a considerable
direct healthcare cost. To our knowledge, this study is
the first financial analysis carried out with the aim of
identifying the therapeutic alternatives most commonly
used in Spain for managing the early stages of MF, to
determine their healthcare resources use and quantify their
associated costs. The lack of national studies with similar
objectives has prevented us from creating comparative
arguments. However, the conclusions observed in this
study are in line with previous publications carried out in
other healthcare environments,35–37 which evidence that
MF patients, even in the early stages, require considerable
use of healthcare resources due to the high frequency of
visits to outpatient care centers and pharmacy departments.
Given the low incidence of this rare disease, limited
literature has been found regarding its management in the
Spanish setting or regarding the use of healthcare
resources. Despite the inherent nature and limitations of
any consultative methodology using a reference expert
panel, the participation and involvement of the Spanish
clinical experts involved in this study have become an
essential factor in achieving the proposed objectives. One
of the limitations of the present study is the lack of
a recommended daily dose defined by WHO
Collaborative Centre for Drugs Statistics Methodology
for topical treatments. This has forced us to apply certain
assumptions during the estimation of topical corticosteroid
Table 3 (Continued).
Base case Minimum scenario Maximum scenario
€, 2018 % €, 2018 % €, 2018 %
Associated maintenance costs 4.57 0.09% 3.66 0.11% 5.49 0.06%
Total cost 5,167.57 100.00% 3,361.65 100.00% 9,742.06 100.00%
Time horizon: 6 months
Pharmaceutical costs (IFNα) 1,676.07 26.17% 1,614.91 38.78% 3,289.64 27.13%
Administration costs (IFNα) 1,464.48 22.87% 916.32 22.01% 2,012.64 16.60%
Phototherapy sessions costs 3,058.02 47.75% 1,540.00 36.98% 6,382.32 52.64%
Lab tests and follow-up visits costs 200.37 3.13% 88.15 2.12% 433.61 3.58%
Associated maintenance costs 5.61 0.09% 4.49 0.11% 6.73 0.06%
Total cost 6,404.55 100.00% 4,163.87 100.00% 12,124.95 100.00%
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Figure 2 Cost of the main alternative treatments in managing the early stages of MF in Spain.
Abbreviations: IFNα, interferon alfa; PUVA, psoralens and ultraviolet A light; TSEBT, total skin electron beam therapy; NB-UVB, narrow-band ultraviolet B light.
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usage per application. Likewise, to estimate the cost of
topical carmustine-based chemotherapy, it was necessary
to consider the acquisition, management, compounding,
control and dispensing processes of various topical car-
mustine preparations in Spain. Given the lack of specific
publications on these pharmaceutical compounding proce-
dures, it was considered that the human resources involved
in these activities would be equivalent to those indicated
by Berlana et al,44 a multicenter cost analysis carried out
in the Spanish setting, which details the human and equip-
ment resources involved in the preparation, management
and compounding for medicinal formulations other than
topical carmustine. Nevertheless, considering the price per
vial of carmustine, the associated compounding activities
represent a limited portion (<5%) of the estimated total
costs of topical carmustine-based chemotherapy. Not to
consider the costs associated to the adverse events man-
agement represent a study limitation, especially due to
differential safety profile of the treatments evaluated.
Therefore, the estimated direct health costs here presented
could be underestimated, especially for the systemic treat-
ments and for the TSEBT. Additionally, the results of this
analysis would be underestimated due to not including the
indirect costs associated to these treatments, especially for
the phototherapies and the TSEBT. This is particularly
relevant for MF-CTCL patients, taking into account their
disease impact in terms of productivity loss.38 The authors
encourage the development of future studies to provide
data regarding the societal impact associated to the avail-
able treatments for MF-CTCL, especially considering the
slowly progressive and chronic features of the disease,
together with the emotional and functional impact of the
disease.9,33,34 Further studies should explore the potential
impact in terms of productivity loss and health-related
quality of life burden associated to the available treatments
for the management of MF-CTCL.
Treatment alternatives identified in this study are congru-
ent with clinical data and treatment information on MF
patients reported by AEDV’s primary cutaneous lymphomas
patient registry,20 and also concur with the treatments recom-
mended for early-stage MF management in the main clinical
practice guidelines.11,30–32 Additionally, the therapeutic
options assessed in this study are consistent with the first
results shown by the AEDV’s primary cutaneous lympho-
mas. The SDTs assessed in this analysis represent 90.8%
(topical corticosteroids), 86.1% (phototherapies), 8.3%
(TSEBT) and 6.0% (topical chemotherapies) of the treat-
ments used for MF patients recorded by the AEDV. With
regard to the systemic treatments assessed in this analysis,
the use of systemic retinoids and IFNα was described by
6.9% and 12.1%, respectively, of MF patients recorded by
the AEDV.20 This is aligned with the indications from the
expert panel consulted during this study, in which the use of
combined therapies including systemic treatments for
patients with early-stage MF is usually suggested for those
non-eligible patients or those with a poor response to SDTs.
Based on the clinical expert panel, topical corticosteroids
constitute the basis of MF management, being offered
through all stages, especially during the initial ones.
However, when topical corticosteroids are used in combina-
tion with other treatments, they are not considered as treat-
ments per se, and the combination is, in general, perceived as
a “monotherapy treatment”. Long-term use of topical steroid
may lead to atrophy and development of striae. This risk
increases with the potency of topical corticosteroid and may
lead to systemic absorption.80 Despite that, topical corticos-
teroids are often used as a symptomatic relief for the skin
manifestations caused by the disease or the concomitant
therapies. Therefore, topical corticosteroids were taken in
the present analysis into account due to their wide use in
clinical practice, particularly among early-stages MF
patients. The lack of a standardized dose for their topical
application forced us to include additional considerations
(eg, amount of product required for each topical application,
baseline body surface area involvement and its evolution
through time). Therefore, the interpretation of topical corti-
costeroids results should be interpreted with caution.
The lack of clear, agreed or homogeneous treatment
algorithms together with the range of treatment options
available means that treating MF-CTCL becomes a highly
individualized process. This, together with the few com-
parative studies available, leads the decision-maker to
choose a specific treatment based on the stage of the
disease, the clinical criteria, patient characteristics, the
safety profile, patient preferences and resources available
in each healthcare center. For this reason, having financial
studies available is essential in order to include opportu-
nity cost and cost-benefit elements among the arguments
for assessing these treatments. Consequently, and taking
advantage of the recently generated evidence from the
AEDV registry of primary cutaneous lymphomas
patients,18,20 we would strongly encourage adding evi-
dence related to healthcare resources use in prospective
or retrospective studies already developed in our setting.
This would not only allow us to corroborate the results of
Dovepress Ortiz-Romero et al
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the current study, but also to promote the development of
further pharmacoeconomic evidence regarding CTCLs.
Conclusions
Despite the available information regarding the clinical
features and comorbidities of MF-CTCL, there are limited
data on the treatment patterns, clinical burden and finan-
cial implications of this rare disease. Results of this ana-
lysis show that topical corticosteroids, despite being
considered as an adjuvant option especially for patients
with generalized skin lesions, and phototherapies remain
the treatments with the lowest direct healthcare costs for
managing early-stage MF patients. In contrast, systemic
retinoids in monotherapy, PUVA in combination with sys-
temic retinoids or IFNα, TSEBT and particularly, topical
carmustine-based chemotherapy are among the treatments
with the highest direct healthcare costs. The results of this
analysis show that the treatments mostly used in Spanish
clinical practice during the early stages of MF represent
considerable associated healthcare costs. This information
may be of interest to all those healthcare professionals
interested in quantifying the financial implications for
healthcare systems resulting from MF treatments, to iden-
tify unmet medical needs, to encourage those treatments
that offer the most benefits, expectations and quality-of-
life for patients and to assess the degree of efficiency of
healthcare systems. In this respect, in order to encourage
an efficient healthcare resources distribution, regardless of
the disease or clinical circumstances, it is essential to
determine the cost of alternative treatments.
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